Executive leader with over a decade of experience leading worldwide pre-clinical and clinical programs in oncology and immune-oncology. Heading multi-disciplinary teams and managing multi-million-dollar budgets in private and publicly traded companies. Prior to joining KAHR, served as Chief Development Officer at Cellect Biotechnology (APOP) and as Senior Director of Oncology at BioLineRx (BLRX). Prior to that held R&D positions at Genentech, a leading biotechnology company, member of the Roche Group.
Drug development professional with over 20 years of clinical and industry experience in Global CRO, big Pharma and Biotechnology companies. Prior to joining KAHR, served as VP Medical Affairs at Immune Pharmaceuticals and as Senior Medical Director at Quark Pharmaceuticals. Prior to that was the Medical Director at BioLineRx and before that worked at Roche and Quintiles developing expertise in the design and conduct of early phase clinical studies.
PhD, VP Research & Development
Research and development senior specialist with over 20 years of industry experience in innovative Biotechnology companies. Prior to joining KAHR, served as VP of R&D in multiple companies including Pluristem Therapeutics, Rosetta Genomics and Quark Pharmaceuticals Prior to that she was the Director of Science & Technology at Quantomics.
Prof. Michal Dranitzki Elhalel
Professor Elhalel is Chief of nephrology and hypertension department. She earned her MD at the Hebrew University and performed her Postdoctoral Fellowship in the laboratory of Professor Tykocinski at the University of Pennsylvania. Dr. Elhalel is an expert in the field of molecular immune regulation and her laboratory has been fully devoted to the research of the DSP technology since 2002.
Iris Pecker, PhD
Executive Director, CMC
Biopharmaceuticals CMC expert and drug development professional with over 20 years’ experience in process development for the production of therapeutic proteins. Prior to KAHR, served as the head of process development at InSight Biopharmaceuticals.